Opus Genetics (IRD) Interest Expenses (2020 - 2026)

Opus Genetics (IRD) reported Interest Expenses of $69000.0 for Q1 2026, up 13.11% quarter-over-quarter from $61000.0 in Q4 2025.

Opus Genetics (IRD) Interest Expenses (2020 - 2026) Analysis & Trends

Opus Genetics (IRD) has 5 years of Interest Expenses data on file, last reported at $69000.0 in Q1 2026.

Interest Expenses for Q1 2026 came in at $69000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $198000.0 (changed N/A YoY), and the FY2025 annual result was $129000.0, changed N/A from the prior year.
Interest Expenses advanced to $69000.0 in Q1 2026 per IRD's latest filing, from $61000.0 in the prior quarter.
Over five years, Interest Expenses peaked at $69000.0 in Q1 2026 and troughed at $4000.0 in Q2 2022.
A 3-year average of $41400.0 and a median of $61000.0 in 2025 frame the typical range for Interest Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-5.50 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-332,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	61,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-5.58 Mn
10	Opus Genetics	355.39 Mn	295.43 Mn	-	69,000.00

Download Data